Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial
2024 · The Lancet. Gastroenterology & hepatology · 36 citations
https://doi.org/10.1016/s2468-1253(24)00074-8